APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Typhoid Vi Polysaccharide Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Typhoid Vi Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026

Report ID 174044020422 December 2025192 pages

Choose your research edition.

Industry ResearchTyphoid Vi Polysaccharide Vaccine Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Typhoid Vi Polysaccharide Vaccine Industry Growth and Trends Forecast to 203278 pages · $3,450 USDMarket StructureGlobal Typhoid Vi Polysaccharide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Typhoid Vi Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Typhoid Vi Polysaccharide Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Typhoid Vi Polysaccharide Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Typhoid Vi Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Typhoid Vi Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Typhoid Vi Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Typhoid Vi Polysaccharide Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Typhoid Vi Polysaccharide Vaccine market include Sanofi Pasteur SA, GSK and Emergent BioSolutions, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Typhoid Vi Polysaccharide Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Typhoid Vi Polysaccharide Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Typhoid Vi Polysaccharide Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Typhoid Vi Polysaccharide Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Typhoid Vi Polysaccharide Vaccine Segment by Company

Sanofi Pasteur SA

GSK

Emergent BioSolutions

Typhoid Vi Polysaccharide Vaccine Segment by Type

Child

Adult

Typhoid Vi Polysaccharide Vaccine Segment by Application

Government Institution

Private Sector

Other

Typhoid Vi Polysaccharide Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Typhoid Vi Polysaccharide Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Typhoid Vi Polysaccharide Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Typhoid Vi Polysaccharide Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Typhoid Vi Polysaccharide Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Typhoid Vi Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Typhoid Vi Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Typhoid Vi Polysaccharide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Typhoid Vi Polysaccharide Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Typhoid Vi Polysaccharide Vaccine industry.

Chapter 3: Detailed analysis of Typhoid Vi Polysaccharide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Typhoid Vi Polysaccharide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Typhoid Vi Polysaccharide Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Typhoid Vi Polysaccharide Vaccine Industry Trends Table 2. Typhoid Vi Polysaccharide Vaccine Industry Drivers Table 3. Typhoid Vi Polysaccharide Vaccine Industry Opportunities and Challenges Table 4. Typhoid Vi Polysaccharide Vaccine Industry Restraints Table 5. Global Typhoid Vi Polysaccharide Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Typhoid Vi Polysaccharide Vaccine Revenue Share by Company (2021-2026) Table 7. Global Typhoid Vi Polysaccharide Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Typhoid Vi Polysaccharide Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Typhoid Vi Polysaccharide Vaccine Average Price (US$/unit) of Company (2021-2026) Table 10. Global Typhoid Vi Polysaccharide Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Typhoid Vi Polysaccharide Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Typhoid Vi Polysaccharide Vaccine Company, Product Type & Application Table 13. Global Typhoid Vi Polysaccharide Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Typhoid Vi Polysaccharide Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Child Table 18. Significant Companies of Adult Table 19. Global Typhoid Vi Polysaccharide Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Typhoid Vi Polysaccharide Vaccine Sales Volume by Type (2021-2026) & (k units) Table 21. Global Typhoid Vi Polysaccharide Vaccine Sales Volume by Type (2027-2032) & (k units) Table 22. Global Typhoid Vi Polysaccharide Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Typhoid Vi Polysaccharide Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Typhoid Vi Polysaccharide Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Typhoid Vi Polysaccharide Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Typhoid Vi Polysaccharide Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Government Institution Table 30. Significant Companies of Private Sector Table 31. Significant Companies of Other Table 32. Global Typhoid Vi Polysaccharide Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Typhoid Vi Polysaccharide Vaccine Sales Volume by Application (2021-2026) & (k units) Table 34. Global Typhoid Vi Polysaccharide Vaccine Sales Volume by Application (2027-2032) & (k units) Table 35. Global Typhoid Vi Polysaccharide Vaccine Sales Volume Share by Application (2021-2026) Table 36. Global Typhoid Vi Polysaccharide Vaccine Sales Volume Share by Application (2027-2032) Table 37. Global Typhoid Vi Polysaccharide Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Typhoid Vi Polysaccharide Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Typhoid Vi Polysaccharide Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application (2021-2026) Table 41. Global Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application (2027-2032) Table 42. Global Typhoid Vi Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Typhoid Vi Polysaccharide Vaccine Sales by Region (2021-2026) & (k units) Table 44. Global Typhoid Vi Polysaccharide Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Typhoid Vi Polysaccharide Vaccine Sales by Region (2027-2032) & (k units) Table 46. Global Typhoid Vi Polysaccharide Vaccine Sales Market Share by Region (2027-2032) Table 47. Global Typhoid Vi Polysaccharide Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Typhoid Vi Polysaccharide Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Typhoid Vi Polysaccharide Vaccine Sales Value Share by Region (2021-2026) Table 50. Global Typhoid Vi Polysaccharide Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Typhoid Vi Polysaccharide Vaccine Sales Value Share by Region (2027-2032) Table 52. Global Typhoid Vi Polysaccharide Vaccine Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Typhoid Vi Polysaccharide Vaccine Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Typhoid Vi Polysaccharide Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Typhoid Vi Polysaccharide Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Typhoid Vi Polysaccharide Vaccine Sales by Country (2021-2026) & (k units) Table 57. Global Typhoid Vi Polysaccharide Vaccine Sales Market Share by Country (2021-2026) Table 58. Global Typhoid Vi Polysaccharide Vaccine Sales by Country (2027-2032) & (k units) Table 59. Global Typhoid Vi Polysaccharide Vaccine Sales Market Share by Country (2027-2032) Table 60. Global Typhoid Vi Polysaccharide Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Typhoid Vi Polysaccharide Vaccine Sales Value Market Share by Country (2021-2026) Table 62. Global Typhoid Vi Polysaccharide Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Typhoid Vi Polysaccharide Vaccine Sales Value Market Share by Country (2027-2032) Table 64. Sanofi Pasteur SA Company Information Table 65. Sanofi Pasteur SA Business Overview Table 66. Sanofi Pasteur SA Typhoid Vi Polysaccharide Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Sanofi Pasteur SA Typhoid Vi Polysaccharide Vaccine Product Portfolio Table 68. Sanofi Pasteur SA Recent Development Table 69. GSK Company Information Table 70. GSK Business Overview Table 71. GSK Typhoid Vi Polysaccharide Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. GSK Typhoid Vi Polysaccharide Vaccine Product Portfolio Table 73. GSK Recent Development Table 74. Emergent BioSolutions Company Information Table 75. Emergent BioSolutions Business Overview Table 76. Emergent BioSolutions Typhoid Vi Polysaccharide Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Emergent BioSolutions Typhoid Vi Polysaccharide Vaccine Product Portfolio Table 78. Emergent BioSolutions Recent Development Table 79. Key Raw Materials Table 80. Raw Materials Key Suppliers Table 81. Typhoid Vi Polysaccharide Vaccine Distributors List Table 82. Typhoid Vi Polysaccharide Vaccine Customers List Table 83. Research Programs/Design for This Report Table 84. Authors List of This Report Table 85. Secondary Sources Table 86. Primary Sources List of Figures Figure 1. Typhoid Vi Polysaccharide Vaccine Product Image Figure 2. Global Typhoid Vi Polysaccharide Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Typhoid Vi Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Typhoid Vi Polysaccharide Vaccine Sales (2021-2032) & (k units) Figure 5. Global Typhoid Vi Polysaccharide Vaccine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Typhoid Vi Polysaccharide Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Child Image Figure 10. Adult Image Figure 11. Global Typhoid Vi Polysaccharide Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Typhoid Vi Polysaccharide Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Typhoid Vi Polysaccharide Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Typhoid Vi Polysaccharide Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Typhoid Vi Polysaccharide Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type (2021-2032) Figure 17. Government Institution Image Figure 18. Private Sector Image Figure 19. Other Image Figure 20. Global Typhoid Vi Polysaccharide Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Typhoid Vi Polysaccharide Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Typhoid Vi Polysaccharide Vaccine Sales Volume Share by Application (2021-2032) Figure 23. Global Typhoid Vi Polysaccharide Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Typhoid Vi Polysaccharide Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application (2021-2032) Figure 26. Global Typhoid Vi Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Typhoid Vi Polysaccharide Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Typhoid Vi Polysaccharide Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Typhoid Vi Polysaccharide Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Typhoid Vi Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Typhoid Vi Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Typhoid Vi Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Typhoid Vi Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Typhoid Vi Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Typhoid Vi Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Typhoid Vi Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Typhoid Vi Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Typhoid Vi Polysaccharide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Typhoid Vi Polysaccharide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Typhoid Vi Polysaccharide Vaccine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Typhoid Vi Polysaccharide Vaccine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Child
  • Adult
Applications
  • Government Institution
  • Private Sector
  • Other
Companies covered
  • Sanofi Pasteur SA
  • GSK
  • Emergent BioSolutions

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Typhoid Vi Polysaccharide Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Typhoid Vi Polysaccharide Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Typhoid Vi Polysaccharide Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Typhoid Vi Polysaccharide Vaccine Market Dynamics
  1. 2.1 Typhoid Vi Polysaccharide Vaccine Industry Trends
  2. 2.2 Typhoid Vi Polysaccharide Vaccine Industry Drivers
  3. 2.3 Typhoid Vi Polysaccharide Vaccine Industry Opportunities and Challenges
  4. 2.4 Typhoid Vi Polysaccharide Vaccine Industry Restraints
3 Typhoid Vi Polysaccharide Vaccine Market by Company
  1. 3.1 Global Typhoid Vi Polysaccharide Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Typhoid Vi Polysaccharide Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Typhoid Vi Polysaccharide Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Typhoid Vi Polysaccharide Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Typhoid Vi Polysaccharide Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Typhoid Vi Polysaccharide Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Typhoid Vi Polysaccharide Vaccine Company Product Type and Application
  8. 3.8 Global Typhoid Vi Polysaccharide Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Typhoid Vi Polysaccharide Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Typhoid Vi Polysaccharide Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Typhoid Vi Polysaccharide Vaccine Market by Type
  1. 4.1 Typhoid Vi Polysaccharide Vaccine Type Introduction
  2. 4.1.1 Child
  3. 4.1.2 Adult
  4. 4.2 Global Typhoid Vi Polysaccharide Vaccine Sales Volume by Type
  5. 4.2.1 Global Typhoid Vi Polysaccharide Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Typhoid Vi Polysaccharide Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Typhoid Vi Polysaccharide Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Typhoid Vi Polysaccharide Vaccine Sales Value by Type
  9. 4.3.1 Global Typhoid Vi Polysaccharide Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Typhoid Vi Polysaccharide Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type (2021-2032)
5 Typhoid Vi Polysaccharide Vaccine Market by Application
  1. 5.1 Typhoid Vi Polysaccharide Vaccine Application Introduction
  2. 5.1.1 Government Institution
  3. 5.1.2 Private Sector
  4. 5.1.3 Other
  5. 5.2 Global Typhoid Vi Polysaccharide Vaccine Sales Volume by Application
  6. 5.2.1 Global Typhoid Vi Polysaccharide Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Typhoid Vi Polysaccharide Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Typhoid Vi Polysaccharide Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Typhoid Vi Polysaccharide Vaccine Sales Value by Application
  10. 5.3.1 Global Typhoid Vi Polysaccharide Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Typhoid Vi Polysaccharide Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application (2021-2032)
6 Typhoid Vi Polysaccharide Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Typhoid Vi Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Typhoid Vi Polysaccharide Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Typhoid Vi Polysaccharide Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Typhoid Vi Polysaccharide Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Typhoid Vi Polysaccharide Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Typhoid Vi Polysaccharide Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Typhoid Vi Polysaccharide Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Typhoid Vi Polysaccharide Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Typhoid Vi Polysaccharide Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Typhoid Vi Polysaccharide Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Typhoid Vi Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Typhoid Vi Polysaccharide Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Typhoid Vi Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Typhoid Vi Polysaccharide Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Typhoid Vi Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Typhoid Vi Polysaccharide Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Typhoid Vi Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Typhoid Vi Polysaccharide Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Typhoid Vi Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
7 Typhoid Vi Polysaccharide Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Typhoid Vi Polysaccharide Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Typhoid Vi Polysaccharide Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Typhoid Vi Polysaccharide Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Typhoid Vi Polysaccharide Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Typhoid Vi Polysaccharide Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Typhoid Vi Polysaccharide Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Typhoid Vi Polysaccharide Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Typhoid Vi Polysaccharide Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Typhoid Vi Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Typhoid Vi Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Typhoid Vi Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi Pasteur SA
  2. 8.1.1 Sanofi Pasteur SA Company Information
  3. 8.1.2 Sanofi Pasteur SA Business Overview
  4. 8.1.3 Sanofi Pasteur SA Typhoid Vi Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Pasteur SA Typhoid Vi Polysaccharide Vaccine Product Portfolio
  6. 8.1.5 Sanofi Pasteur SA Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK Typhoid Vi Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GSK Typhoid Vi Polysaccharide Vaccine Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 Emergent BioSolutions
  14. 8.3.1 Emergent BioSolutions Company Information
  15. 8.3.2 Emergent BioSolutions Business Overview
  16. 8.3.3 Emergent BioSolutions Typhoid Vi Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Emergent BioSolutions Typhoid Vi Polysaccharide Vaccine Product Portfolio
  18. 8.3.5 Emergent BioSolutions Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Typhoid Vi Polysaccharide Vaccine Value Chain Analysis
  2. 9.1.1 Typhoid Vi Polysaccharide Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Typhoid Vi Polysaccharide Vaccine Sales Mode & Process
  6. 9.2 Typhoid Vi Polysaccharide Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Typhoid Vi Polysaccharide Vaccine Distributors
  9. 9.2.3 Typhoid Vi Polysaccharide Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst